MedPharm to develop new XF-drug formulations
October 10, 2019
Destiny Pharma appoints MedPharm to develop new XF‐platform drug formulations as treatments for dermal and ocular infections.
MedPharm is pleased to announce it’s appointment as Destiny Pharma’s expert partner to develop new topical formulations of the Company’s novel XF‐platform compounds. Destiny Pharma (AIM: DEST) is a clinical-stage biotechnology company focused on the development of novel antimicrobial drugs. These new treatments for dermal and ocular infections are part of its second clinical program to address the global problem of anti‐microbial resistance (AMR). MedPharm is a world-leading contract provider of topical and transdermal product design and formulation development services using
sophisticated in vitro models to de‐risk development programs.
The XF platform has already delivered a Phase 2 ready candidate, XF‐73 nasal gel, for the prevention of post‐surgical infections, that will begin Phase 2b testing in 2019. MedPharm will develop new formulations containing Destiny Pharma’s XF‐platform compounds for the treatment of a number of topically treated infections, including diabetic foot ulcers and ophthalmic infections. MedPharm is a well‐established, global leader in topical product development with a track record in developing a wide variety of formulations, from early concept stage through clinical development to full product approval.
Neil Clark, CEO of Destiny Pharma commented:
“We are pleased to be working with MedPharm and using their globally recognized expertise to develop effective, patient‐friendly formulations of XF and DPD drugs from our novel antimicrobial XF‐platform. There is an unmet medical need for novel anti-infectives that address dermal and ocular infections with a significantly reduced level of antimicrobial resistance. We look forward to developing improved, targeted formulations with MedPharm to take into future pre‐clinical and clinical studies.”
Eugene Ciolfi, President & CEO of MedPharm commented:
“MedPharm is very excited to be a part of this project and working in close collaboration with Destiny Pharma to address this unmet medical need. Our rigorous methodology, incorporating our novel and world-leading in vitro performance testing, will ensure that we deliver fully optimized formulations and de‐risk these important development programs.”
Read the full story here.
Notes to editors
About Destiny Pharma
Destiny Pharma is an established, clinical stage, innovative biotechnology company focused on the development of novel medicines from its XF platform that represent a new approach to the treatment of infectious disease. These potential new medicines are being developed to address the need for new drugs for the prevention and treatment of life‐threatening infections caused by antibiotic‐resistant bacteria, often referred to as “superbugs”. Tackling anti‐microbial resistance has become a global imperative recognized by the WHO and the United Nations, as well as the G7 and the G20 countries. For further information, please visit www.destinypharma.com.
MedPharm is the world’s leading contract provider of topical and transdermal product design and formulation development services. MedPharm are experts at reducing risk and accelerating development times for generic and proprietary pharmaceutical customers through their unique, cost-effective and industry-leading performance testing models. Well established as the global leaders in dermatology, nail, mucosal membrane, and transdermal product development, MedPharm can also offer innovative solutions for ophthalmic and airway preparations recognised for their scientific rigour by regulators and investors. MedPharm has fully established R&D centers in the USA and UK and has its global HQ in Guildford, UK.